Regulus (NASDAQ:RGLS) Therapeutics Inc., a biopharmaceutical company, has entered into a significant licensing agreement with The University of Texas System on behalf of The University of Texas at Southwestern Medical Center (UTSW). The agreement, formalized on Tuesday, grants Regulus exclusive worldwide rights to certain patents and technology for treating autosomal dominant polycystic kidney disease (ADPKD).
Under the terms of the deal, Regulus will have exclusive, worldwide rights to manufacture, distribute, use, import, market, and sell products covered by the jointly-owned patents. Additionally, the company has acquired non-exclusive rights to necessary technical information and know-how related to the patents.
Regulus has committed to diligently advance the development and commercial availability of the licensed products and services, with specific clinical, regulatory, and sales milestones to be achieved by predetermined dates.
The financial terms of the agreement include an initial payment of $62,500 to UTSW, alongside the reimbursement of certain patent expenses. Regulus will also make milestone payments up to $1.6 million for clinical and regulatory achievements and up to $2.5 million for commercial milestones. Moreover, tiered royalties on net sales of licensed products or services will be paid to UTSW, with a minimum annual royalty following the first sale.
The agreement also stipulates payments to UTSW for the first sublicense granted by Regulus and subsequent sublicenses. The license remains in effect until the expiration or termination of the patents unless Regulus opts for earlier termination with a 90-day notice, or UTSW terminates due to payment arrears or repeated breaches by Regulus.
In other recent news, Regulus Therapeutics has made significant advancements in its clinical trials. The company has completed patient enrollment for Cohort 4 in their Phase 1b study of RGLS8429, a drug under investigation for treating Autosomal Dominant Polycystic Kidney Disease. The study, involving 26 patients, is designed to measure changes in urinary polycystins, total kidney volume, and overall kidney function. Topline data from this study is expected to be released in early 2025. Analyst firm H.C. Wainwright has maintained a Buy rating on Regulus Therapeutics, reflecting their confidence in the potential of RGLS8429.
In addition to this, the company is preparing for an end-of-Phase 1 meeting with the FDA, anticipated to occur near the end of 2024. This meeting is expected to be crucial in finalizing the design for the upcoming Phase 2/3 pivotal trial in 2025. Furthermore, Canaccord Genuity has maintained a Buy rating on Regulus Therapeutics, highlighting the potential of the company's anti-miRNA-17 therapy, currently in Phase 1b development for Autosomal Dominant Polycystic Kidney Disease. This therapy has shown early signs of safety and efficacy, reinforcing Canaccord Genuity's confidence in the stock. These are among the recent developments in Regulus Therapeutics' clinical program.
InvestingPro Insights
Regulus Therapeutics Inc .'s recent licensing agreement with The University of Texas System marks a significant step in its pursuit of treatments for autosomal dominant polycystic kidney disease (ADPKD). However, investors should consider the company's financial position and market performance when evaluating this development.
According to InvestingPro data, Regulus has a market capitalization of $92.96 million, reflecting its current market valuation. The company's price-to-book ratio of 0.95 suggests that the stock is trading slightly below its book value, which could indicate potential undervaluation.
InvestingPro Tips highlight that Regulus holds more cash than debt on its balance sheet, which may provide some financial flexibility as it pursues the development of licensed products. However, the company is quickly burning through cash and is not profitable over the last twelve months, with a negative gross profit of $25.6 million in the last twelve months as of Q2 2024.
These financial metrics underscore the importance of the milestone payments and potential royalties outlined in the licensing agreement, as they could provide crucial revenue streams for Regulus. The company's ability to meet the clinical, regulatory, and sales milestones specified in the agreement will be critical for its financial health and future growth prospects.
Investors interested in a deeper analysis of Regulus Therapeutics can access additional InvestingPro Tips, with 9 more tips available on the platform to further inform investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.